{"id":78033,"date":"2019-01-04T00:00:50","date_gmt":"2019-02-01T06:12:48","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/78033\/"},"modified":"2019-02-01T14:12:52","modified_gmt":"2019-02-01T06:12:52","slug":"260ade5254","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/78033\/","title":{"rendered":"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f"},"content":{"rendered":"
\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/p>\n

\u6628\u5929BMS\u6536\u8d2dCelgene\u7684740\u4ebf\u7f8e\u5143\u5e76\u8d2d\u5408\u5e76\u5ba3\u5e03\u540e\uff0c\u533b\u836f\u5237\u5c4f\uff01<\/span><\/strong>\u968f\u540eBMS\u80a1\u4ef7\u622a\u6b62\u6536\u76d8\u5927\u8dcc13.26%\uff0cCelgene\u622a\u6b62\u6536\u76d8\u5927\u6da820.69%\u3002\uff08<\/span>\u7531\u6b64\u53ef\u89c1\u534e\u5c14\u8857\u5e76\u4e0d\u770b\u597dBMS\u7684\u6536\u8d2d\uff0c\u53cd\u800c\u5229\u597dCelgene<\/span>\uff09\u8fd9\u4e2a\u5408\u5e76\u9884\u8ba1Q3\u5b8c\u6210\uff0c\u662f\u5426\u987a\u5229\u4ea4\u5272\u62ed\u76ee\u4ee5\u5f85\uff0c\u7f8e\u80a1\u8d44\u672c\u5e02\u573a\u6bd4\u8f83\u6210\u719f\uff0c\u5728MNC\u90fd\u5728\u7cbe\u7b80\u548c\u8d44\u672c\u5316\u7684\u540c\u65f6\uff0c\u8fd9\u4e2adeal\u4f1a\u5f15\u53d1\u4eca\u5e74\u7684\u70ed\u70b9\u8ba8\u8bba\u3002BMS\u4e0d\u4f1a\u8d85\u8d8aRoche\u5728\u80bf\u7624\u9886\u57df\u7684\u9886\u5148\u5730\u4f4d\uff0cCelgene\u4e5f\u4e0d\u4f1a\u662fGenentech\uff01<\/span><\/p>\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/p>\n

\u524d\u5929\uff0c\u6fb3\u65af\u5eb7\u751f\u7269\u5ba3\u5e03\u5b8c\u6210A\u8f6e\u8d853\u4ebf\u4eba\u6c11\u5e01<\/span>\u878d\u8d44\uff0c\u5fb7\u742a\u533b\u836f\u5b8c\u6210B\u8f6e1.2\u4ebf\u7f8e\u5143<\/span><\/span>\u878d\u8d44\uff0c\u8bfa\u8bda\u5065\u534e\u5b8c\u6210<\/span>C\u8f6e1.6\u4ebf\u7f8e\u5143<\/span>\u878d\u8d44\uff0c\u5eb7\u4e43\u5fb7\u533b\u836f\u5b8c\u6210B\u8f6e5500\u4e07\u7f8e\u5143\u878d\u8d44\u3002\u82cf\u8f69\u5802\u836f\u4e1a\u5728NASDAQ\u4e0a\u5e02\u52df\u96c6\u8d44\u91d1<\/span>1000\u4e07\u7f8e\u5143<\/span>\u5de6\u53f3\uff081\u6708\u5e95\u4e5f\u6709\u4e00\u5bb6biotech\u5728NASDAQ\u4e0a\u5e02\uff0c\u76ee\u524d\u5728pre-IPO\u8f6e\u878d\u8d44\uff09<\/strong>\u3002\u8fd9\u4e00\u6761\u6761\u751f\u7269\u79d1\u6280\u516c\u53f8\u7684\u878d\u8d44\u4ee4\u4eba\u5174\u594b\uff0c\u671f\u5f852019\u66f4\u591a\u521b\u4e1a\u8005\u4e0d\u4f1a\u5728\u878d\u8d44\u5bd2\u51ac\u4e2d\u5ea6\u8fc7\u3002<\/strong><\/span><\/p>\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/p>\n

\u7d27\u63a5\u7740\u56fd\u5185\u77e5\u540d\u7684\u4e24\u5bb6Biotech<\/span>\u5955\u5b89\u6d4e\u4e16\u751f\u7269<\/span><\/strong>\u548c<\/span>\u8fc8\u535a\u65af<\/span><\/strong>1\u67082\u65e5\u5ba3\u5e03\u5408\u5e76\u5ba3\u5e03\u5408\u5e76\uff0c\u6210\u7acb<\/span>Transcenta<\/strong><\/span>\u3002\uff08\u8fd9\u4e2a\u521b\u65b0\u836f\u516c\u53f8\u5408\u5e76\u4e5f\u662f\u7ee7\u53bb\u5e74\u6d77\u548c\u836f\u7269\u4e0e\u8bfa\u8fc8\u897f\u533b\u836f\u5408\u5e76\u6210\u7acb<\/span>\u6d77\u548c\u751f\u7269<\/span><\/strong>\uff09\u3002\u7531\u4e8e\u8fd1\u5e74\u4e2d\u56fd\u8d44\u672c\u6295\u8d44\u7684\u521b\u65b0\u836f\u8fc7\u591a\uff0c\u66f4\u591a\u4e0d\u540cportfolio\u8981\u4e48\u5408\u4f5c\uff0c\u8981\u4e48\u7ade\u4e89\uff0c\u8981\u4e48\u5408\u5e76\uff01<\/span>\u770b\u6765\u540c\u4e00\u8d44\u672c\u65d7\u4e0b\u7684biotech\u9884\u8ba1\u7ec4\u6210\u66f4\u5f3a\u5927\u7684\u72ec\u89d2\u517d\uff0c\u8fd9\u6837\u53bb\u6e2f\u80a1\u4ea6\u6216\u662f\u7f8e\u80a1\u624d\u6709\u6838\u5fc3\u7ade\u4e89\u529b\u3002<\/span><\/strong><\/p>\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/span><\/span><\/strong><\/p>\n

\u5408\u4f5c\u4ea4\u6613\u8fd1\u51b51\u67082\u65e5\uff0c\u6b63\u5927\u5929\u6674\u53c8\u4e0e\u836f\u7269\u751f\u7269\u7684\u53cc\u7279\u5f02\u6027\u6297\u4f53\u5e73\u53f0Wuxibody\u5408\u4f5c\u5f00\u53d1\u4e00\u4e2a\u9879\u76ee<\/span>\uff08\u8fd9\u4e2a\u5e73\u53f0\u4e0a\u4e2a\u6708\u521a\u4e0e\u5b89\u79d1\u751f\u7269\u4e5f\u5408\u4f5c\uff09\uff0c\u836f\u660e\u751f\u6001\u5708\u5df2\u7ecf\u5f62\u6210\uff0c\u671f\u671b\u770b\u5230\u66f4\u591a\u6709\u6570\u636e\u9a71\u52a8\u7684\u5408\u4f5c\u3002\u6fb3\u65af\u5eb7\u751f\u7269\u4e0e\u749f\u6cfd\u751f\u7269\u7684CMO\u5408\u4f5c<\/span>\uff0c\u749f\u6cfd\u5c06\u59d4\u6258\u6fb3\u65af\u5eb7\u751f\u4ea7R18A\u4e09\u671f\u4e34\u5e8a\u6837\u54c1\u3001\u8fdb\u884c\u751f\u7269\u5236\u54c1\u8bb8\u53ef\u7533\u8bf7\uff08BLA\uff09\u76f8\u5173\u5de5\u4f5c\u3001\u53ca\u4e0a\u5e02\u540e\u5546\u4e1a\u5316\u751f\u4ea7\u3002\u77f3\u836f\u96c6\u56e2\u572812\u6708\u4efd\u8d2d\u4e70\u5c1a\u5065\u751f\u7269\u7684PD-1\u6297\u4f53\u76ee\u524d\u5df2\u7ecf\u5b8c\u6210<\/span>\uff0c\u77f3\u836f\u96c6\u56e2\u4f5c\u4e3a\u6e2f\u80a1\u9f99\u5934\u4f01\u4e1a\uff0c2018\u5e74\u9879\u76ee\u5f15\u8fdb\u548c\u6295\u8d44\u5e03\u5c40\u8bf8\u591a\uff08\u5e76\u8d2d\u6d25\u66fc\u7279\u3001\u6295\u8d44\u6d77\u548c\u751f\u7269\u3001\u52b2\u65b9\u836f\u4e1a\uff09\uff0c\u66f4\u591a\u4fe1\u606f\u60c5\u51b5\u6682\u4e0d\u65b9\u4fbf\u5bf9\u5916\u62ab\u9732\u3002\u8d1d\u8fbe\u836f\u4e1a<\/span>\u7ee712\u670828\u65e5\u62ab\u97322.3\u4ebf\u5143\u8d2d\u4e70\u76ca\u65b9\u751f\u7269<\/span>\u7684EGFR-T790M\u6291\u5236\u5242D-0316\u5927\u4e2d\u534e\u533a\u6743\u76ca\u540e\uff0c2\u65e5\u53c8\u62ab\u9732\u4e0e\u6b27\u6d32Merus<\/span>\u8fbe\u6210EGFR\/cMET\u53cc\u7279\u5f02\u6027\u6297\u4f53MCLA-129\u4e2d\u56fd\u533a\u6743\u76ca\uff0c\u5177\u4f53\u7ec6\u8282\u672a\u62ab\u9732\uff0c\u5947\u602a\u7684\u662f\u5148\u58f0\u836f\u4e1a<\/span>\u4e4b\u524d\u8ddfMerus<\/span>\u7684\u5408\u4f5c\u4e1d\u6beb\u65e0\u8fdb\u5c55\u3002<\/p>\n

\u518d\u6765\u4e00\u6761\u4eca\u5929\u62ab\u9732\u7684license\uff1a<\/strong><\/span><\/p>\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/p>\n

\u7f8e\u56fd\u7ebd\u7ea6\u6c34\u725b\u57ce\uff0c2019\u5e741\u67083\u65e5 Athenex\uff0cInc.\uff08NASDAQ\uff1aATNX\uff09\uff0c\u662f\u4e00\u5bb6\u5168\u7403\u751f\u7269\u5236\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u764c\u75c7\u53ca\u76f8\u5173\u75be\u75c5\u7684\u65b0\u7597\u6cd5\uff0c\u4eca\u5929\u5ba3\u5e03\u5df2\u4e8e2018\u5e7412\u670830\u65e5\u901a\u8fc7\u5176\u5b50\u516c\u53f8\u4e0e\u91cd\u5e86\u656c\u4e1c\u541b\u5353\u533b\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f8\uff08\u201c\u91cd\u5e86\u656c\u4e1c\u533b\u836f\u201d\uff09\u8fbe\u6210\u8bb8\u53ef\u548c\u5408\u4f5c\u534f\u8bae\uff0c\u8bb8\u53ef\u91cd\u5e86\u656c\u4e1c\u533b\u836f\u5728\u4e2d\u56fd\u5883\u5185\u72ec\u5bb6\u53d1\u5c55\u548c\u5546\u4e1a\u5316KX2-391\uff0c\u7528\u4e8e\u6cbb\u7597\u4eba\u7c7b\u5149\u5316\u6027\u89d2\u5316\u75c5\u548c\u80bf\u7624\u9002\u5e94\u75c7\u3002<\/p>\n

\n

KX2-391\uff0c\u4ea6\u79f0\u4e3aKX-01\uff0c\u662f\u4e00\u79cd\u9996\u521b\u53ccSrc\u6fc0\u9176\u548c\u5fae\u7ba1\u86cb\u767d\u805a\u5408\u6291\u5236\u5242\u3002KX2-391\u818f\u5242\u662f\u7528\u4e8e\u6cbb\u7597\u75c5\u60c5\u53d1\u5c55\u81f3\u665a\u671fIII\u671f\u5149\u5316\u6027\u89d2\u5316\u75c5\u7684\u5916\u7528\u836f\u7269\u4ea7\u54c1\u3002\u5149\u5316\u6027\u89d2\u5316\u75c5\u662f\u4e00\u79cd\u5e38\u89c1\u7684\u76ae\u80a4\u75c5\uff0c\u901a\u8fc7\u7d2b\u5916\u7ebf\u5149\u635f\u4f24\u8bf1\u53d1\uff0c\u5bfc\u81f4\u76ae\u80a4\u53d8\u539a\u3001\u9cde\u7247\u72b6\u6216\u786c\u76ae\u3002\u5982\u679c\u7f3a\u4e4f\u6cbb\u7597\uff0c\u75c5\u53d8\u6709\u53d1\u5c55\u6210\u4e3a\u9cde\u72b6\u7ec6\u80de\u764c\u7684\u98ce\u9669\uff0c\u56e0\u6b64\u5efa\u8bae\u7531\u76ae\u80a4\u79d1\u533b\u751f\u8fdb\u884c\u6cbb\u7597\u3002\u6b64\u5916\uff0c\u5176\u4ed6\u4ee5KX2-391\u4e3a\u6709\u6548\u6210\u5206\u7684\u5019\u9009\u836f\u7269\u4e5f\u6b63\u540c\u6837\u5f00\u53d1\u7528\u4e8e\u80bf\u7624\u9002\u5e94\u75c7\u3002<\/p>\n

\u4f9d\u636e\u8be5\u534f\u8bae\u7684\u6761\u6b3e\u548c\u6761\u4ef6\uff0cAthenex\u5c06\u5728Athenex \u7684\u77e5\u8bc6\u4ea7\u6743\u8303\u56f4\u5185\u6388\u4e88\u91cd\u5e86\u656c\u4e1c\u533b\u836f\u4e00\u9879\u72ec\u5bb6\u8bb8\u53ef\uff0c\u8bb8\u53ef\u5176\u5728\u4e2d\u56fd\u5927\u9646\uff08\u4e0d\u5305\u62ec\u9999\u6e2f\u3001\u6fb3\u95e8\u548c\u53f0\u6e7e\uff09\u5546\u4e1a\u5316\u542bKX2-391\u7684\u5916\u7528\u548c\u53e3\u670d\u4ea7\u54c1\u3002Athenex\u5c06\u6536\u5230\u5408\u51711450\u4e07\u7f8e\u5143\u7684\u9884\u4ed8\u8d39\u7528\u3002Athenex\u8fd8\u6709\u8d44\u683c\u83b7\u5f97\u9ad8\u8fbe1500\u767e\u4e07\u7f8e\u5143\u7684\u5176\u4ed6\u5f00\u53d1\u91cc\u7a0b\u7891\u4ed8\u6b3e\u3002<\/span>\u6b64\u5916\uff0c\u8be5\u534f\u8bae\u89c4\u5b9a\u4e86\u4ece15\uff05\u5f00\u59cb\u7684\u5206\u5c42\u8bb8\u53ef\u8d39\uff0c\u5e76\u4e14\u5c06\u968f\u9500\u552e\u989d\u800c\u9010\u6b65\u589e\u52a0\u3002<\/p>\n

2019\u5e74\u9884\u6d4b\uff1a<\/span><\/strong>\u4e2d\u5c0f\u4f01\u4e1a\u8f6c\u578b\u88ab\u5e76\u8d2d\u4f1a\u589e\u52a0\uff0c\u878d\u8d44\u4f1a\u6bd4\u8f83\u56f0\u96be\uff0c\u4f30\u503c\u8c03\u6574\u5728\u5373\uff08\u4e0a\u8ff0\u878d\u8d44\u5b8c\u6210\u7684\u6709\u8c03\u6574\u4f30\u503c\uff09\uff0c\u65b0\u52df\u96c6\u57fa\u91d1\u4f9d\u7136\u4f1a\u964d\u4f4e\uff08\u673a\u6784\u548c\u6bcd\u57fa\u91d1\u6ca1\u94b1\u4e86\uff0c\u4e0a\u5e02\u516c\u53f8\u505aLP\u4f1a\u975e\u5e38\u8c28\u614e\uff09\uff0c\u6295\u8d44\u4eba\u8f6c\u578b\u4f1a\u66b4\u589e\uff08\u52df\u6295\u7ba1\u9000\u5f3a\u608d\u7684\u4e0d\u5fc5\u62c5\u5fc3\uff09\uff0c\u4e0a\u5e02\u836f\u4f01\u5bf9\u4e8e\u5916\u90e8\u521b\u65b0\u7684\u9879\u76ee\u8d8a\u6765\u8d8a\u6e34\u671b\uff0c\u751f\u7269\u521d\u521b\u516c\u53f8\u9762\u4e34\u540e\u7eed\u878d\u8d44\u548c\u5546\u4e1a\u5316\u538b\u529b\uff0c\u533b\u4fdd\u8c03\u6574\u5728\u6240\u96be\u514d\uff0c\u5e26\u91cf\u91c7\u8d2d\u8d8b\u52bf\u4e0d\u4f1a\u6539\u53d8\u3002\u73af\u4fdd\u65b0\u89c4\u4e0b\uff0c\u539f\u6599\u836f\u9886\u57df\u6295\u8d44\u4f1a\u589e\u591a\u3002\u603b\u4e4b\uff0c\u653f\u7b56\u8c03\u6574\u671f\u4f9d\u7136\u6709\u592a\u591a\u673a\u4f1a\uff0c\u73cd\u60dc\u5df2\u6709\uff0c\u62e5\u62b1\u672a\u6765\u3002<\/span><\/span>\u5c0f\u8d8b\u52bf\u5c31\u662f\u5408\u4f5c\u3002\u3002\u3002\u3002<\/strong><\/span><\/p>\n

1.Nuvo Pharmaceuticals Announces Completion of the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo and other Related Assets<\/em><\/h3>\n

2.Lupin plans expansion, eyes Europe growth via acquisitions and launches<\/em><\/h3>\n

3.Promethera Biosciences Announces Investment by ITOCHU Corporation and a Broad Strategic Collaboration to Access the Asian Markets<\/em><\/h3>\n

4.Acer Therapeutics Announces In-license of Osanetant from Sanofi<\/em><\/h3>\n

5.Sanofi ends deal with MyoKardia to develop small-molecule drugs for heart diseases<\/em><\/h3>\n

6.Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China<\/em><\/h3>\n

7.Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement<\/em><\/h3>\n

8.APRINOIA Therapeutics Licenses Tau PET Imaging Tracer APN-1607 to Celgene<\/em><\/h3>\n

9.NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU in the Republic of Korea<\/em><\/h3>\n

10.Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL<\/em><\/h3>\n

11.Adlai Nortye Announces Clinical Collaboration with Merck to Evaluate Adlai Nortye’s AN0025 (EP4 Antagonist) in Combination with KEYTRUDA (pembrolizumab) in Patients with Solid Tumors<\/em><\/h3>\n

12.Ascletis’ IND Filing for Its Third HCV Drug ASC21 Accepted by NMPA<\/em><\/h3>\n

13.AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39<\/em><\/h3>\n

14.Takeda Announces Multiple Therapy Collaborations to Advance the Company\u2019s Novel Immuno-Oncology Portfolio<\/em><\/h3>\n

15.Merck Exercises Option for NGM Bio\u2019s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes<\/em><\/h3>\n

16.Bristol-Myers Squibb to buy Celgene for around $74 billion<\/em><\/h3>\n

17.Vyome raises $22M to advance dermatology pipeline<\/em><\/h3>\n

18.Sojournix Completes $44 Million Series C Financing<\/em><\/h3>\n

19.Corbus Pharmaceuticals Announces Strategic Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Lenabasum in Japan for Systemic Sclerosis and Dermatomyositis<\/em><\/h3>\n

20.ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics<\/em><\/h3>\n

21.Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Products to Treat B -Mediated Autoimmune Diseases<\/em><\/h3>\n

22.Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics<\/em><\/h3>\n

23.Mavupharma Selects First Immuno-Oncology Clinical Candidate MAVU-104, an Oral STING Pathway Enhancer<\/em><\/h3>\n

24.Onxeo Announces Identification of Predictive Biomarkers for AsiDNA, its First-in-Class DNA Damage Response Inhibitor<\/em><\/h3>\n

25.Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi in the U.S. with Coeptis Pharmaceuticals<\/em><\/h3>\n

26.Hikma announces exclusive agreement with Sciecure Pharma for niche injectable anti-viral medicine<\/em><\/h3>\n

27.Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers<\/em><\/h3>\n

28.Immusoft Raises $20 Million in Series B Financing<\/em><\/h3>\n

29.Amunix Announces Licensing Agreement with Merck for ProTIA Immune Activator Platform<\/em><\/h3>\n

30.Shanghai-Based Hexaell Biotech Secures 50 million RMB ($7.3 million) Series A Financing From Hyfinity Investments<\/em><\/h3>\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/em><\/p>\n

2019|\u7b2c\u4e00\u5c4a\u836f\u878d\u5708CBV\u9ad8\u5cf0\u8bba\u575b\u8bf7\u626b\u4e0b\u65b9\u4e8c\u7ef4\u7801\u62a5\u540d\uff0c\u540d\u989d\u6709\u9650<\/strong><\/h3>\n


<\/p>\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/p>\n

\"\u65b0\u5e74\u65b0\u6c14\u8c61\uff0c\u533b\u836f\u884c\u4e1a\u4ecd\u662f\u70ed\u70b9\uff0c\u5c0f\u8d8b\u52bf\u4f1a\u5982\u4f55\uff1f\"<\/p>\n

\n<\/blockquote><\/div>\n","protected":false},"excerpt":{"rendered":"

\u6628\u5929BMS\u6536\u8d2dCelgene\u7684740\u4ebf\u7f8e\u5143\u5e76\u8d2d\u5408\u5e76\u5ba3\u5e03\u540e\uff0c\u533b\u836f\u5237\u5c4f\uff01\u968f\u540eBMS\u80a1\u4ef7\u622a\u6b62\u6536\u76d8\u5927\u8dcc13.26%\uff0cC […]<\/p>\n","protected":false},"author":1,"featured_media":78034,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/78033"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=78033"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/78033\/revisions"}],"predecessor-version":[{"id":78043,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/78033\/revisions\/78043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/78034"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=78033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=78033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=78033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}